View Future GrowthOctopus Biosafety 과거 순이익 실적과거 기준 점검 0/6지난 몇 년간 Octopus Biosafety 의 실적에 대한 데이터가 부족합니다.핵심 정보n/a순이익 성장률n/a주당순이익(EPS) 성장률Machinery 산업 성장률10.65%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Dec 2024최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Aug 12New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Shares are highly illiquid. Minor Risk Market cap is less than US$100m (€16.5m market cap, or US$19.0m).Board Change • Aug 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Gérard Ménéroud was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Jun 18New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€656k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (172% average daily change). Negative equity (-€656k). Market cap is less than US$10m (€2.22m market cap, or US$2.56m). Minor Risk Revenue is less than US$5m (€1.1m revenue, or US$1.2m).New Risk • Jun 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 170% a day. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (170% average daily change). Revenue is less than US$1m (€656k revenue, or US$746k). Market cap is less than US$10m (€1.66m market cap, or US$1.88m). Minor Risk Latest financial reports are more than 6 months old (reported December 2023 fiscal period end).공고 • May 10Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025. Location: 9 rue du danemark, auray France공고 • Aug 09Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024. Location: cyanophy labooratoires, 140 av du 12 juillet 1998, aix en provence FranceNew Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$300k). Market cap is less than US$10m (€1.09m market cap, or US$1.18m).New Risk • Dec 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$306k). Market cap is less than US$10m (€811.0k market cap, or US$893.2k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).New Risk • Jun 11New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€636k). Revenue has declined by 19% over the past year. Revenue is less than US$1m (€537k revenue, or US$577k). Market cap is less than US$10m (€1.34m market cap, or US$1.44m).공고 • Nov 25Octopus Biosafety SA (ENXTPA:MLOCT) acquired TIBOT Technologies SAS.Octopus Biosafety SA (ENXTPA:MLOCT) acquired TIBOT Technologies SAS on November 24, 2022.Octopus Biosafety SA (ENXTPA:MLOCT) completed the acquisition of TIBOT Technologies SAS on November 24, 2022.Is New 90 Day High Low • Dec 01New 90-day low: €1.50The company is down 50% from its price of €3.00 on 02 September 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 6.0% over the same period.매출 및 비용 세부 내역Octopus Biosafety가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BST:OCR 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Dec 240-10031 Dec 231-20031 Dec 220-10031 Dec 211-11031 Dec 201-11031 Dec 190-11031 Jul 17100030 Jun 160000양질의 수익: OCR가 고품질 수익을 갖고 있는지 판단하기에는 데이터가 부족합니다.이익 마진 증가: 지난 1년 동안 OCR의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 OCR의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: OCR의 지난해 수익 성장률을 5년 평균과 비교하기에 데이터가 부족합니다.수익 대 산업: OCR의 지난 해 수익 증가율이 Machinery 업계 평균을 상회했는지 판단하기에 데이터가 부족합니다.자기자본이익률높은 ROE: OCR는 현재 수익성이 없으므로 자본 수익률이 음수(0%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YCapital-goods 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/23 17:38종가2026/08/20 00:00수익2024/12/31연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Octopus Biosafety SA는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • Aug 12New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Shares are highly illiquid. Minor Risk Market cap is less than US$100m (€16.5m market cap, or US$19.0m).
Board Change • Aug 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Gérard Ménéroud was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Jun 18New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€656k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (172% average daily change). Negative equity (-€656k). Market cap is less than US$10m (€2.22m market cap, or US$2.56m). Minor Risk Revenue is less than US$5m (€1.1m revenue, or US$1.2m).
New Risk • Jun 03New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 170% a day. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (170% average daily change). Revenue is less than US$1m (€656k revenue, or US$746k). Market cap is less than US$10m (€1.66m market cap, or US$1.88m). Minor Risk Latest financial reports are more than 6 months old (reported December 2023 fiscal period end).
공고 • May 10Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025Octopus Biosafety SA, Annual General Meeting, Jun 17, 2025. Location: 9 rue du danemark, auray France
공고 • Aug 09Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024Octopus Biosafety SA, Annual General Meeting, Sep 13, 2024. Location: cyanophy labooratoires, 140 av du 12 juillet 1998, aix en provence France
New Risk • Jun 09New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$300k). Market cap is less than US$10m (€1.09m market cap, or US$1.18m).
New Risk • Dec 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (30% average weekly change). Negative equity (-€1.4m). Revenue has declined by 48% over the past year. Revenue is less than US$1m (€277k revenue, or US$306k). Market cap is less than US$10m (€811.0k market cap, or US$893.2k). Minor Risk Latest financial reports are more than 6 months old (reported December 2022 fiscal period end).
New Risk • Jun 11New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2021. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€636k). Revenue has declined by 19% over the past year. Revenue is less than US$1m (€537k revenue, or US$577k). Market cap is less than US$10m (€1.34m market cap, or US$1.44m).
공고 • Nov 25Octopus Biosafety SA (ENXTPA:MLOCT) acquired TIBOT Technologies SAS.Octopus Biosafety SA (ENXTPA:MLOCT) acquired TIBOT Technologies SAS on November 24, 2022.Octopus Biosafety SA (ENXTPA:MLOCT) completed the acquisition of TIBOT Technologies SAS on November 24, 2022.
Is New 90 Day High Low • Dec 01New 90-day low: €1.50The company is down 50% from its price of €3.00 on 02 September 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 6.0% over the same period.